On November 13, 2025, the WANECAM 2 project organized a Symposium during the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) held in Toronto, Canada. The presenters included Prof. Abdoulaye Djimde, Montserrat Blazquez-Domingo (EDCTP Representative), Cornelis Winnips, Martin Grobusch, and Fatim Ballo. Entitled “Towards the First Non-artemisinin Combinations for falciparum Malaria:…
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance Basel, November 12, 2025 – Novartis today announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum). The novel non-artemisinin antimalarial, which was developed with Medicines for Malaria Venture (MMV), met…
On August 22, 2025, in the gracious presence of Their Majesties the Emperor and Empress of Japan, Professor Abdoulaye Djimdé received the Fifth Hideyo Noguchi Africa Prize, presented by Prime Minister Ishiba during a solemn ceremony held in Tokyo. Our warmest congratulations to Professor Abdoulaye Djimdé for this prestigious distinction, which celebrates African research and…
The annual WANECAM 2 congress, combined with a Project Management Board meeting, took place on December 4-5, 2024, at the Hôtel Boulevard in Libreville, Gabon. The event was attended by Prof. Abdoulaye Djimdé, coordinator of the consortium, Dr. Rella Manego, principal investigator for the Gabonese site, and Prof. Ghyslain Mombongoma. Highlights of the Meeting Outlook…
From October 28 to 31, 2024, an enriching training on writing scientific articles was held in a hybrid format at the DELGEME Plus training center in Point G. This initiative brought together 60 participants, all eager to enhance their scientific writing skills and tackle the challenges associated with scientific publication. A Training Focused on Participants’…
On Thursday, April 25, 2024, WANECAM 2 in partnership with the National Malaria Control Program celebrated World Malaria Day under the theme: Promoting health equity, gender equality and human rights. Highlighting the disproportionate effect of the malaria endemic on women and girls, as care providers and patients affected by the disease. The event took place at the…
New Orleans, 15 November 2024 – The West African Network for Clinical Trials of Antimalarial Drugs (WANECAM2) consortium is pleased to announce positive results from the Phase 2b KALUMI study of the novel, non-artemisinin drug ganaplacide combined with a new once-daily formulation of lumefantrine. KALUMI is a Phase 2 randomized, open-label, non-inferiority study evaluating the…
Context The involvement of young girls at all stages of their lives in Science is a major focus of the WANECAM 2 project, which encourages young girls to study Science in order to promote the female gender. Hence, WANECAM 2 in partnership with the Amazons of the Faculty of Medicine and Odonto-stomatology (FMOS) and the…
Context As part of its capacity building activities, the WANECAM 2 project has initiated a pedagogical workshop for MRTC-Parasito PhDs for the review of theses with the aim of better formalizing the follow-up of all PhDs to enhance the quality of human resources that MRTC-Parasito trains locally. Objective This activity took place from 19 to…
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria Basel, November 23, 2022 — As the threat of resistance to current malaria treatments grows1,2, Novartis and MMV announce the decision to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase 3 development for the treatment…
